Is KYNB or KZIA more undervalued in 2026?

CirclFi compares Kyntra Bio, Inc. (KYNB) and Kazia Therapeutics Limited (KZIA) using 13 institutional-grade valuation models. KYNB has a Quality of Company score of 5.3/10 while KZIA scores 4.3/10.

Which is a better buy — KYNB or KZIA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KYNB and KZIA valuations compare?

KYNB at $6.90 and KZIA at $12.78 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KYNB vs KZIA Valuation Comparison 2026 — Intrinsic Value Analysis

KYNB

Pharmaceutical Preparations

Kyntra Bio, Inc.

Quality

5.3

out of 10

Value Trap

WARN

Price

$6.90

Last close

Models

7/13

Active

KZIA

Pharmaceutical Preparations

Kazia Therapeutics Limited

Quality

4.3

out of 10

Value Trap

SAFE

Price

$12.78

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	KYNB Fair Value	KYNB Upside	KZIA Fair Value	KZIA Upside
Bayesian DCF	Intrinsic	$16.17	+132.7%	$5.81	-54.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$16.33	+136.6%	$2.95	-76.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KYNB vs KZIA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KYNB vs KZIA — Which Stock Is More Undervalued?

KYNB scores higher with a 5.3/10 quality rating vs KZIA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kyntra Bio, Inc. (KYNB) and Kazia Therapeutics Limited (KZIA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KYNB currently trades at $6.90 with a QOC of 5.3/10, while KZIA trades at $12.78 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).